Ann Child Neurol Search

CLOSE


Ann Child Neurol > Volume 32(4); 2024 > Article
Wander, Meena, Choudhary, Peer, and Singh: Pediatric Headache: A Comprehensive Review

Abstract

Pediatric headache is a common condition that often results in frequent outpatient visits. There are two broad etiological groups of headaches—primary and secondary headaches—with the former being more prevalent. Migraine, a type of primary headache, shares similarities with those experienced by adults, albeit with some variations in diagnostic criteria. The secondary causes of headache should be differentiated from the primary headaches with proper clinical evaluation and focussed investigations. The management of migraine focusses on lifestyle modifications, behavioral therapy, and pharmacotherapy for acute episodes and long-term preventive therapy. There are many novel promising treatment modalities. This review article provides an overview of pediatric headache epidemiology, classification, and pathophysiology and then elaborates on management and prevention strategies.

Introduction

Headache is one of the most common complaints encountered in children and adolescents, often leading to outpatient and emergency visits [1]. The primary task for a pediatrician or pediatric neurologist in headache evaluation is to differentiate the small fraction of children with secondary headaches from the majority who have a primary headache disorder, such as migraine. The initial steps in evaluation involve a thorough history, general physical examination, and complete neurological assessment. If the initial assessment raises suspicions of a secondary etiology, additional diagnostic testing, including neuroimaging and cerebrospinal fluid (CSF) examination, may be necessary in some cases.

Epidemiology and Etiology

Studies evaluating the prevalence of headache in children have reported substantial variation, with prevalence rates ranging between 8% and 88% in children [2]. A meta-analysis found the prevalence, assessed at intervals from 1 month and the lifetime, was 58.4% in children and adolescents [3]. In a study of American children, 17.1% reported experiencing frequent or severe headaches, including migraines, within the last 12 months. The occurrence of headaches rises with age, reaching a prevalence rate of up to 27% among 16- to 18-year-olds. Sex variations in headaches become noticeable after puberty, as girls demonstrate a higher prevalence rate than boys [4]. Headaches occur more frequently in children with a positive family history [5-7]. The overall estimated prevalence of migraine is around 8% in children, assessed over a period between 6 months and the lifetime [3].

1. Etiology

Headaches in children can be categorized into primary, where pain is a result of the headache condition itself, and secondary, where pain serves as a symptom of an underlying condition. Migraine and tension-type headaches are the most frequently encountered types of primary headaches in children [8]. Cluster headache, a type of primary headache in children, exhibits similar characteristics to headaches in adults but is rare among young children [9]. Upper respiratory tract infections are the commonest cause of secondary headaches that prompt emergency visits. Meningitis, hydrocephalus, and intracranial tumours are common etiologies of life-threatening headache in children [10]. Frequently, no diagnosis can be reached despite an extensive evaluation. In a study involving 48,575 children aged 5 to 17 years who had headache disorders, about 19% were identified with primary headaches, 1.1% were diagnosed with secondary headaches, and 79.7% did not receive a formal diagnosis [11].

2. Pathophysiology

The pathophysiology of headaches is intricate, with genetic and environmental factors playing crucial roles in the development of migraine, tension-type headache, and cluster headache. However, identifying the specific genes involved has proven to be a challenging task. Familial hemiplegic migraine, which is linked to mutations in the calcium voltage-gated channel subunit alpha1 A (CACNA1A), ATPase Na+/K+ transporting subunit alpha 2 (ATP1A2), and sodium voltage-gated channel alpha subunit 1 (SCN1A) genes, and cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is associated with a notch receptor 3 (NOTCH3) gene mutation, stand out as the most extensively studied headache disorders with a genetic foundation [12].
The vascular theory of migraines, according to which migraine stems from blood vessel dilation and that the aura is a result of vasoconstriction, is now deemed invalid, as evidenced by magnetic resonance angiography studies [13]. A typical migraine episode consists of four phases: the prodromal or premonitory phase, the aura phase, the headache phase, and the post-dromal phase [14]. The premonitory phase is characterized by irritability, fatigue, difficulty in concentration, nausea, or pallor. Functional neuroimaging studies suggest involvement of the hypothalamus in the premonitory phase, as well as during the migraine attack phase [15]. The migraine aura constitutes a reversible neurological phenomenon impacting approximately one-third of all migraine sufferers and occasionally overlapping with the headache phase. The underlying mechanism of this phase is thought to involve cortical spreading depolarization (CSD) across the cortex. CSD is marked by a brief excitation period, followed by a prolonged depression of cortical activity. Originating from the occipital lobes, it propagates anteriorly, dissipates at the central sulcus, and influences neurotransmitter levels, ionic balance, and blood flow [16]. The headache phase is characterized by the activation of the trigeminocervical complex. Neuropeptides, particularly calcitonin gene-related peptide (CGRP), are involved in trigeminal activation and have emerged as a potential target for therapeutic interventions in migraine patients [15]. A simplified overview of the pathophysiology of migraine is depicted in Fig. 1.
The development of cluster headaches involves interactions among the trigemino-vascular pathway, trigeminal autonomic reflex, hypothalamus, and the neuropeptides CGRP and pituitary adenylate cyclase-activating polypeptide [17]. In tension-type headaches, the pain is thought to stem from myofascial structures and is heightened by central sensitization mechanisms. This central sensitization involves an imbalance in neurotransmitters such as CGRP, nitric oxide, neurokinin-A, glutamate, substance-P, serotonin, and endogenous peptide systems [18].

Classification

The International Classification of Headache Disorders, third edition (ICHD-3) provides comprehensive criteria for diagnosing primary headaches, secondary headaches, neuropathies, and facial pain disorders [19]. It is important to note that primary and secondary headaches are not mutually exclusive; individuals with a primary headache may experience a headache that is exacerbated by a cause of secondary headaches.

1. Primary headache

The most prevalent types of primary headaches in children are migraine and tension-type headaches. Cluster headache is a type of trigeminal autonomic cephalalgia and is relatively rare in children.

1) Migraine

In children, migraine diagnosis adheres to the criteria for migraine in adults as outlined in ICHD-3, albeit with some distinctions related to symptom duration and location. While migraine in adults typically lasts for 4 to 72 hours (when not treated or unsuccessfully treated), the duration in children can be as short as 2 hours. Headache is more often bilateral in children as compared to adult population; the pattern of unilateral pain often emerges during late adolescence or early adulthood. The photophobia and phonophobia may be evident based on the behavior of young children [19]. Children and adolescents, like adults, also undergo the premonitory and postdrome phases. Premonitory symptoms are observed in up to two-thirds of adolescents and include fatigue, irritability, mood changes, yawning, alterations in urination patterns, neck stiffness, sensitivity to light, nausea, and facial pallor or dark circles around the eyes [20]. Recognizing premonitory symptoms can be advantageous for the early identification and management of migraine attacks. After the headache phase, children may also manifest a post-dromal phase. In a study, 82% of patients reported a post-headache phase characterized by symptoms such as thirst, excessive somnolence, visual blurring, and food cravings [21]. The diagnostic criteria for migraine headaches are shown in Table 1.
The ICHD-3 recognizes a cluster of conditions usually observed in childhood and potentially linked to an elevated risk of developing migraine. There is evidence indicating that these conditions may serve not only as precursors but also as manifestations of migraine [22]. Diagnosing episodic syndromes relies on a thorough clinical evaluation and the exclusion of alternative diagnoses. Some metabolic disorders featuring episodic vomiting and seizure disorders can mimic these episodic syndromes, emphasizing the need for careful consideration and differential diagnosis. These episodic syndromes are summarized in Table 2 [23-28]. In the ICHD-3 classification, infantile colic and alternating hemiplegia of childhood are included in the appendix of ICHD-3 but not in the text.

2) Tension-type headache

Tension-type headache is categorized as a primary headache disorder, presenting as a diffuse pain characterized by a pressing or tightening sensation. The diagnostic criteria of tension-type headache are summarized in Table 3. The severity typically ranges from mild to moderate, and it is not aggravated by physical activity. While it may be accompanied by photophobia or phonophobia, nausea and vomiting are not typically observed. Tension-type headache is further classified as infrequent, frequent and chronic based on the frequency of the headache according to the ICHD-3 classification [19].

3) Cluster headache

Cluster headache is a type of trigeminal autonomic cephalalgia. It is characterized by intense to extremely severe pain located in the frontal or orbito-frontal region, accompanied by autonomic features including conjunctival injection, rhinorrhoea, or sweating. The diagnostic criteria of cluster headache are summarized in Table 3. Cluster headache is rare in children.
The clinical characteristics of migraine, tension-type headache, and cluster headache are summarized in Table 4 [29].

2. Secondary headache

Secondary headaches are caused by an underlying condition. This term includes cases where a primary headache is exacerbated by an underlying condition. Common causes of secondary headaches include central nervous system infections, trauma, stroke, idiopathic intracranial hypertension, hypertension, and pain arising from the ear, cranium, eye, neck, nose, sinus, teeth, or other local involvement [19].

Approach to Pediatric Headache

1. History and clinical examination

It is important to directly obtain information about headache from the child whenever possible. Older children and adolescents can provide detailed and accurate descriptions of their headaches. Parents can offer valuable insights into the child's behavior, school performance, developmental milestones, and family history. A thorough account of a child's behavior during acute attacks can provide insights into additional symptoms. For instance, a decreased appetite during attacks might indicate nausea, and a preference for reclining in a quiet, dark room could suggest sensitivity to light and sound.
The primary objective of obtaining a headache history in children is to identify red flag signs that may indicate the presence of a secondary cause of headache. An occipital headache without red flags in the history and normal findings on a neurological examination does not warrant imaging [30]. Nevertheless, the coexistence of an occipital headache with an abnormal neurological examination in children has been linked to brain tumours [31]. Features that warrant heightened concern and further evaluation are as follows [32]:
 1. A new onset and worsening headache
 2. Headache that awakens the child or occurs consistently upon awakening from sleep
 3. Occipital headache
 4. Age <6 years
 5. Personality change
 6. Focal neurological deficit (ataxia, weakness, diplopia)
 7. Nuchal rigidity
 8. Headache associated with postural variation in intensity
 9. Headache intensifying with coughing or straining
 10. Recurring thunderclap headaches
 11. Focal neurological deficits, or an abnormal finding in a comprehensive neurological assessment (including abnormalities in an eye examination, papilledema, cerebellar signs)
 12. Signs of systemic disease or known systemic disorders in children. The clinician should look for neurocutaneous stigmata, developmental delays, and explore potential neurovascular and neurogenetic conditions that could be linked to secondary headaches.
A thorough clinical examination is crucial to avoid overlooking secondary causes of headaches. This involves assessing vital signs to identify hypertension or fever. Impaired growth could indicate a chronic underlying disease, while macrocephaly might be attributed to underlying hydrocephalus. A fundus examination is necessary to rule out papilledema in relevant clinical settings, along with an assessment of visual acuity [33]. A comprehensive neurological examination is equally vital, as serious neurological conditions with secondary headaches are often associated with multiple neurological deficits on examination [31].

2. Neuroimaging

The American Academy of Neurology (AAN) and Child Neurology Society advises against imaging when the clinical history lacks associated risk factors, and the child's examination is normal [34]. Despite these recommendations, neuroimaging in routine practice is frequently done even in the absence of red flags [35]. Whenever clinically indicated, magnetic resonance imaging is preferred over computed tomography. Contrast imaging is preferred in the setting of possible central nervous system infection. The presence of thunderclap headache necessitates additional angiography.

3. Other investigations

Routine laboratory investigations have a limited role in the evaluation of headache in absence of relevant clinical features. A CSF examination should be done if central nervous system infection is suspected or to document the opening pressure. Electroencephalography should be avoided in the assessment of episodic headaches [34].

Management of Migraine

1. Acute management

The goal of acute management is to terminate the migraine attack early, enabling a return to normal activities. General measures include avoiding environmental noise, isolating the child in a silent and dark room, and encouraging the child to go to sleep. Intravenous hydration is warranted if the child presents to emergency room [36].
Medications useful in acute treatment of migraines include analgesics such as nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, triptans, and antiemetics. The effectiveness may vary; thus, a trial of different medications may be required on an individual basis. Randomized placebo-controlled trials have demonstrated the effectiveness of both acetaminophen and ibuprofen in the acute treatment of migraines in children. A three-way crossover trial comparing acetaminophen and ibuprofen for the acute treatment of migraines in children found that paracetamol showed greater efficacy at 1 hour post-administration, whereas ibuprofen was found to be more effective overall [37]. A double-blind, placebo-controlled trial concluded that ibuprofen is effective for acute migraine treatment. A sex difference was found, with boys showing significantly higher rates of response [38]. Naproxen has been found to be effective compared to a placebo [39]. A combination of naproxen with sumatriptan has been evaluated in adolescents and was found to be both safe and effective [40]. A double-blind clinical trial investigating intravenous ketorolac and prochlorperazine reported that ketorolac was successful in 55% of children, but was inferior to prochlorperazine (85%) [41].
Triptans are agonists of serotonin receptors with an affinity for 5-hydroxytryptamine (5-HT1B/1D) receptors [42] The U.S. Food and Drug Administration (FDA) has approved four triptans for the acute treatment of migraines in children aged 12 to 17 years: almotriptan, zolmitriptan, rizatriptan, and sumatriptan/naproxen. Triptans should be given as single dose, administered once in a 24-hour period. Although administering a second dose 2 hours after the first may be deemed safe, the effectiveness of such a regimen has not been definitively established [43]. In cases where nausea and vomiting are prominent, the early administration of an antiemetic may alleviate symptoms and promote better sleep. Commonly used antiemetics include promethazine, prochlorperazine, metoclopramide, and ondansetron. The doses of various drugs for acute management of headache in children are given in Table 5. According to a Cochrane review, ibuprofen surpasses placebo in effectiveness, while paracetamol does not show superiority over placebo. Triptans have been found to be superior to placebo and associated with minor side effects. Additionally, the combination of sumatriptan and naproxen combination has demonstrated superiority over placebo, whereas oral dihydroergotamine did not show superiority over placebo [44]. It is crucial to highlight that triptans should not be used in children with ischemic vascular disease or arrhythmias [45].
The management of migraine includes lifestyle modifications, acute treatment, and preventive treatment. Children may need a combination of these three approaches. The treatment objectives should aim at consistently and effectively minimizing symptoms with the fewest possible side effects, facilitating a prompt return to normal function [35,46]. The choice among treatment options depends on multiple factors, including the clinical context, patient values and preferences, comorbid conditions, the adverse effect profile, availability, cost, insurance coverage, and clinician familiarity with specific treatments.
Neuromodulation is not approved by the FDA or recommended by the AAN guidelines for the acute treatment of headaches in migraine. However, various non-invasive neuromodulation modalities have been tried such as transcranial magnetic stimulation (TMS), non-invasive vagal nerve stimulation, and non-invasive electrical stimulation.
An approach to management of acute migraine with summary of available modalities is given in Fig. 2.

1) Lifestyle modifications

A SMART plan should be considered while counseling the child and parents.
 S: Sleep: sufficient sleep with constant bedtimes and wake-up times on weekdays and weekends.
 M: Meals: avoid fasting or skipping meals
 A: Adequate hydration: increasing water intake
 R: Regular exercise: aerobic exercise 30-40 minutes three times a week
 T: Avoid triggers
The counseling should consist of advice on sleep hygiene, adequate hydration, regular food intake, and exercise. It is crucial to determine whether insufficient sleep, dehydration, or skipping meals are triggers. The American Academy of Sleep Medicine has issued a consensus statement outlining the recommended sleep duration for children and adolescents, taking into account their respective ages [47]. For optimal health, adolescents need a minimum of 8 hours of sleep at night. However, due to their physiologically delayed sleep phase and the fact that high schools often start earlier than would be ideal for their waking hours, adolescents frequently face challenges in obtaining the recommended amount of sleep [48]. This often leads to changes in bedtimes and wake times between weekdays and weekends, as children and adolescents try to compensate for lost sleep by sleeping on weekends.
Excessive screen time may be linked to primary headaches in children, and it is important to reduce the time spent on screens [49]. Studies in the adult population have suggested a correlation between decreased physical activity and a heightened prevalence of migraines. Furthermore, a study found that participating in 40 minutes of aerobic exercise three times a week yielded results comparable to using topiramate for the preventive treatment of migraines in adults [50,51]. It is essential to consider other risk factors for headaches in children, including potential stressors, such as instances of physical or emotional abuse, as well as incidents of bullying [52]. Children with migraines often report comorbidities including anxiety and mood disorders. It is crucial to address these additional health concerns as they have been identified as potential factors that can impact both headaches and overall quality of life [53].

2) Behavioral interventions

Cognitive behavioral therapy (CBT) is an evidence-based modality for pediatric migraines. It provides coping mechanisms to effectively deal with pain and assists in modifying factors that precipitate headaches. The components of CBT include psychoeducation (information about the prevalence and nature of the disease), self-monitoring, coping skills, parent training and relapse prevention [54]. A systematic review and meta-analysis of 14 studies found that the odds ratio for a 50% or greater reduction in headache activity after at least 3 months of CBT was 9.18 (95% confidence interval, 5.69 to 14.81; P<0.001) [55].

3) Pharmacological management

The focus should be on identifying the treatment that provides maximum benefits with minimum side effects. Children and parents should be counselled on monitoring possible adverse effects. To minimize these effects, medications should be initiated at the lowest effective dose and then incrementally adjusted to attain the desired target dose. Preventive pharmacological treatment is indicated when headaches are frequent, prolonged, or disabling. Additionally, preventive therapy is employed when patients fail to respond to or are intolerant of acute treatment. The preventive medications discussed here are confined to those that have been studied specifically in children. Possibly useful oral agents include cyproheptadine, propranolol, amitriptyline, topiramate, cinnarizine, and flunarizine. Injectable agents include CGRP antagonists and botulinum toxin. In addition, non-invasive neurostimulation is a promising modality for preventing migraine in children.

(1) Topiramate

The FDA has approved the use of topiramate in migraine prevention among children aged 12 to 17 years old. In a quasi-experimental study, topiramate resulted in significant reduction in disability associated with migraine [56]. However, a three-arm trial spanning 24 weeks reported no difference in the reduction of either headache frequency or disability among children and adolescents with migraines when treated with amitriptyline, topiramate, or a placebo [57]. The common side effects of topiramate include cognitive slowing, paresthesia, and weight loss. Other potentially serious side effects include renal stones, glaucoma, and teratogenicity.

(2) Sodium valproate

There have been no placebo-controlled trials conducted for valproate in the prevention of migraines in children. A randomized trial identified no discernible difference between valproate and propranolol in terms of their effectiveness in preventing migraines [58]. The side effects of valproate encompasses alopecia, tremor, teratogenicity, hepatotoxicity, pancreatitis, leukopenia, and thrombocytopenia.

(3) Amitriptyline

The Childhood and Adolescent Migraine Prevention (CHAMP) trial reported no benefit of amitriptyline over placebo and topiramate [57]. Significant side effects of tricyclic antidepressants such as amitriptyline are dry mouth, constipation, sedation, an increase in appetite, weight gain, occasional orthostatic hypotension, and cardiotoxicity [59].

(4) Propranolol

Studies on the use of propranolol for preventing pediatric migraines have produced mixed results. When low-dose propranolol was compared with amitriptyline, both were found to be equally effective in reducing the number of migraine attacks in children, with propranolol demonstrating fewer side effects [60]. A trial concluded that, at both the 4- and 8-week post-treatment marks, propranolol was found to be less effective than pregabalin in preventing migraines [61]. Propranolol may lead to side effects such as fatigue, sleep disturbance, and light-headedness.

(5) Cinnarizine

Cinnarizine, which exerts dual functions as an antihistamine and a calcium channel blocker, appears to be effective in migraine prevention. In a placebo-controlled trial involving children aged 5 to 17 with migraines, the cinnarizine group demonstrated a more than 50% reduction in headache frequency as compared to the placebo. Potential side effects of cinnarizine may include mild drowsiness and, less commonly, weight gain [62].

(6) Flunarizine

Observational studies have reported the efficacy of flunarizine, revealing that over half of those treated experienced a headache frequency reduction of more than 50% [63]. The AAN/American Headache Society guidelines concluded that there is insufficient evidence to ascertain whether flunarizine is more effective than a placebo in reducing migraine attacks in children [64]. Nevertheless, a systematic review and meta-analysis conducted in 2019, which included studies involving both adults and children, concluded that flunarizine demonstrated modest effectiveness in reducing headache frequency compared to a placebo and appeared to be effective in children [65]. Weight gain and sedation are the most frequent adverse effects of flunarizine.

(7) Botulinum toxin

The effectiveness of botulinum toxin injections in children is currently uncertain. Trials in adults have produced conflicting results regarding the efficacy of onabotulinumtoxin-A (BoNTA) injections in reducing the frequency of headaches in chronic migraine [66,67]. A systematic review of seven studies showed only modest reductions in headache frequency, duration, and intensity among responders [68]. BoNTA is administered every 3 months via intramuscular injection. The most common adverse effects observed in treated groups are neck pain and musculoskeletal pain [66]. A retrospective study in children and adolescents found that BoNTA injections significantly reduced headache severity and frequency [69]. BoNTA is currently not approved for adolescents <18 years of age.

(8) CGRP antagonists

CGRP is associated with the transmission of painful stimuli, as it is found in unmyelinated sensory nerve fibres. In adults, studies have shown that monoclonal antibodies to CGRP or its receptor are efficacious for migraine prevention. These antibodies are typically administered as a once-per-month self-injection. However, it is important to note that CGRP antagonists are not approved for patients under the age of 18.

4) Non-pharmacological modalities

(1) Transcranial magnetic stimulation

The FDA in the United States has approved a device designed for the acute treatment and prevention of migraines in adolescents (aged 12 years and above) and adults [70]. This device delivers brief-duration, rapidly alternating, or pulsed magnetic fields directed towards specific regions of the brain to induce electric currents. It operates on the principle of single-pulse TMS. A pilot study found TMS to be safe in adolescents aged 12 to 17 years for migraine prevention [71].

(2) Transcutaneous nerve stimulation

Transcutaneous nerve stimulation (TNS) has shown promising results in adult population. A meta-analysis concluded that TNS is effective and well-tolerated but needs more randomized trials [72]. Nevertheless, it is important to highlight that there is currently a lack of robust evidence supporting the effectiveness of this intervention in children.

Management of Tension-Type Headache and Cluster Headache

The management of tension-type headache in pediatric patients lacks clear guidelines. Pharmacological prevention is not deemed necessary for all patients, and non-pharmacological approaches such as physical exercise, behavioral therapy, or psychological counseling may be helpful [73]. The acute attack may be terminated using NSAID or non-NSAID analgesics. There is a lack of randomized trials and commonly used preventive medications are amitriptyline, gabapentin, and topiramate.
The management of cluster-type headaches in children is also devoid of evidence-based recommendations. A systematic review of case reports has determined that oxygen inhalation, sumatriptan nasal spray, and ergotamine derivatives are the most effective treatments for acute attacks. Additionally, verapamil, gabapentin, indomethacin, and valproate have been identified as effective options for preventing these headaches [9].

Conclusion

Pediatric headache is a prevalent condition in children, leading to substantial morbidity and frequent healthcare visits. The primary culprits are often primary headaches and acute viral infections. The initial assessment is essential for identifying potential warning signs, excluding secondary or life-threatening causes of headaches, and minimizing unnecessary investigations. Migraine is the most significant and common type of headache in children and adolescents. Prompt acute management of migraines involves supportive care and analgesics, but there is a lack of clear evidence-based recommendations for preventive therapy in children, highlighting a need for further research in this area. Newer modalities including non-invasive neuro-simulation botulinum toxin and CGRP antagonists are promising and emerging therapies.

Conflicts of interest

No potential conflict of interest relevant to this article was reported.

Author contribution

Conceptualization: AW, AKM, and SP. Methodology: AW and AKM. Visualization: AKM and SP. Writing - original draft: AW, AKM, PKC, and RS. Writing - review & editing: AW, AKM, PKC, SP, and RS.

Fig. 1.
A simplified depiction of migraine pathophysiology.
acn-2024-00521f1.jpg
Fig. 2.
Approach to the management of acute migraine attacks. NSAID, non-steroidal anti-inflammatory drug.
acn-2024-00521f2.jpg
Table 1.
The ICHD-3 diagnostic criteria of migraine in children
Migraine without aura
 1. Minimum 5 headache attacks that fulfil the criteria 2 to 4.
 2. Headache attack lasting for 2-72 hours.
 3. Headache has at least two out of the four following characteristics:
  Unilateral in location
  Pulsating nature
  Moderate or severe headache in intensity
  Aggravated during physical activity or headache leads to avoidance of physical activity
 4. At least one of the following characters during the headache:
  Nausea and/or vomiting
  Photophobia and phonophobia
 5. Not explained by an alternative ICHD-3 diagnosis
Migraine with aura
 1. Minimum 2 attacks fulfilling criteria 2 and 3
 2. One or more of the following reversible aura symptoms:
  Motor
  Sensory
  Visual
  Speech and/or language
  Brainstem
  Retinal
 3. At least three of the following six characteristics:
  At least one aura spreads gradually over 5 minutes
  2 or more aura symptoms occur in succession
  Each aura symptom lasts 5-60 minutes
  At least one aura symptom is unilateral
  At least one aura symptom is positive
  The aura is accompanied, or followed by headache within 60 minutes
 4. Not explained by another ICHD-3 diagnosis

ICHD-3, International Classification of Headache Disorders, third edition.

Table 2.
Episodic syndromes associated with migraine
Condition Age group Clinical features Duration of attacks Associated features
Cyclic vomiting syndrome [23] 4-7 years Episodic and recurrent vomiting Hours to days Predictable periodicity and attacks lasting for more than an hour to up to10 days
Abdominal migraine [24] 10-12 years Episodic periumbilical dull abdominal pain Hours to days Loss of appetite, nausea, vomiting, and pallor
Benign paroxysmal vertigo [25] 4-6 years Sudden onset of vertigo manifesting as dizziness or ataxia Minutes to hours Ataxia, nystagmus, pallor, and a sense of fearfulness
Benign paroxysmal torticollis [26] Early infancy (2-5 months) Recurring and episodic unilateral head tilting that happens at consistent intervals Minutes to days Irritability, ataxia, pallor, malaise, vomiting
Infantile colic [27] Early infancy (peaks at 6 weeks) Excessive crying Exceeding 3 hours daily, occurring more than 3 days weekly, persisting for a duration surpassing 3 weeks No abdominal distension or vomiting
Alternating hemiplegia of childhood [28] Infancy Episodes of alternating hemiplegia Each episode lasts for minutes to days Encephalopathy, paroxysms of dystonia, choreoathetoid movements, and autonomic dysfunction
Table 3.
The ICHD-3 diagnostic criteria of tension-type headache and cluster headache
Tension-type headache (infrequent)
 1. Minimum of 10 headache episodes occurring for less than 1 day per month on average (<12 day/year) and fulfilling criteria 2-4
 2. Lasting from 30 minutes to 7 days
 3. At least two of the following four characteristics:
  Bilateral location
  Pressing or tightening characteristic
  Mild-moderate intensity
  Not exacerbated by routine physical activity
 4. Both of the following:
  No nausea or vomiting
  Not more than one of either photophobia or phonophobia
 5. Not better explained for by other ICHD-3 diagnosis
Cluster headache
 1. At least five attacks satisfying criteria 2-4
 2. Severe to very severe unilateral orbital, supra-orbital and/or temporal pain lasting 15 minutes to 3 hours if not treated
 3. One or both of the following:
  a) At least one of the following symptoms or signs, ipsilateral to the headache:
   Conjunctival injection and/or lacrimation
   Nasal congestion and/or rhinorrhoea
   Eyelid edema
   Forehead and facial sweating
   Miosis and/or ptosis
  b) A sense of restlessness or agitation
 4. Headache frequency between 1 every other day and 8 per day
 5. Not better explained by other ICHD-3 diagnosis

ICHD-3, International Classification of Headache Disorders, third edition.

Table 4.
Summary of the clinical characteristics of primary headaches
Migraine Tension-type headache Cluster headache
Premonitory phase Present Absent Present
Aura Less frequent in children than in adults. Seen in around 5% of children with migraine [29] Absent Absent
Location Bifrontal/bitemporal Bilateral Unilateral
Duration At least 2 hours 30 minutes to 7 days Less than 3 hours
Headache characteristic Pulsatile/throbbing, moderate to severe Pressing, mild to moderate Sharp/stabbing. Severe and associated with ipsilateral autonomic features
Nausea and vomiting Present Absent Absent
Photophobia and phonophobia Present Maybe present Absent
Aggravation by physical activity Present Absent Absent
Table 5.
Drugs for acute management of migraine in children
Drug Dose
1 Acetaminophen 10-15 mg/kg/dose
Maximum of 5 doses in a day
2 Ibuprofen 10 mg/kg/dose
Maximum 400 mg per dose and maximum daily dose is 2,400 mg per day.
3 Naproxen 5-7 mg/kg/dose
Maximum 1,000 mg per day
4 Ketorolac Intravenous: 0.5 mg/kg/dose
Maximum dose is 30 mg per dose.
Oral: 1 mg/kg/dose
Maximum dose 10 mg per dose and maximum daily dose 40 mg per day
5 Rizatriptan Less than 40 kg: 5 mg
More than 40 kg: 10 mg
(FDA labelled for 6 to 17 years)
6 Zolmitriptan nasal spray Less than 40 kg: 2.5 mg
More than 40 kg: 5 mg
(FDA labelled for 12 to 17 years)
7 Sumatriptan /naproxen combination Less than 40 kg: 10 mg/60 mg
More than 40 kg: 85 mg/500 mg
(FDA labelled for 12 to 17 years)
8 Almotriptan Less than 40 kg: 6.25 mg
More than 40 kg: 12.5 mg
(FDA labelled for 12 to 17 years)
9 Promethazine 0.25 to 0.5 mg/kg/dose
Prochlorperazine 0.15 mg/kg
Maximum dose is 10 mg per dose.
10 Metoclopramide 0.1 to 0.15 mg/kg/dose
Maximum dose is 10 mg per dose.

FDA, U.S. Food and Drug Administration.

References

1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-22.
pmid pmc
2. Nieswand V, Richter M, Gossrau G. Epidemiology of headache in children and adolescents: another type of pandemia. Curr Pain Headache Rep 2020;24:62.
crossref pmid pmc pdf
3. Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol 2010;52:1088-97.
crossref pmid
4. Lateef TM, Merikangas KR, He J, Kalaydjian A, Khoromi S, Knight E, et al. Headache in a national sample of American children: prevalence and comorbidity. J Child Neurol 2009;24:536-43.
crossref pmid pmc pdf
5. Anttila P, Metsahonkala L, Sillanpaa M. School start and occurrence of headache. Pediatrics 1999;103:e80.
crossref pmid pdf
6. Aromaa M, Rautava P, Sillanpaa M, Helenius H, Ojanlatva A. Familial occurrence of headache. Cephalalgia 1999;19 Suppl 25:49-52.
crossref pmid pdf
7. Russell MB, Ostergaard S, Bendtsen L, Olesen J. Familial occurrence of chronic tension-type headache. Cephalalgia 1999;19:207-10.
crossref pmid pdf
8. How CH, Chan WS. Headaches in children. Singapore Med J 2014;55:128-30.
crossref pmid pmc
9. Bastos SN, Barbosa BL, Silva SF, Krymchantowski AG, Jevoux C, Krymchantowski A, et al. Cluster headache in children and adolescents: a systematic review of case reports. Dev Med Child Neurol 2021;63:1155-60.
crossref pmid pdf
10. Conicella E, Raucci U, Vanacore N, Vigevano F, Reale A, Pirozzi N, et al. The child with headache in a pediatric emergency department. Headache 2008;48:1005-11.
crossref pmid
11. Kernick D, Stapley S, Campbell J, Hamilton W. What happens to new-onset headache in children that present to primary care?: a case-cohort study using electronic primary care records. Cephalalgia 2009;29:1311-6.
crossref pmid pdf
12. Van Den Maagdenberg AM, Terwindt GM, Haan J, Frants RR, Ferrari MD. Genetics of headaches. Handb Clin Neurol 2010;97:85-97.
crossref pmid
13. Amin FM, Asghar MS, Hougaard A, Hansen AE, Larsen VA, de Koning PJ, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol 2013;12:454-61.
crossref pmid
14. Shankar Kikkeri N, Nagalli S. Migraine with aura. In: StatPearls [Internet]. Treasure Island: StatPearls Publishing; 2023 [cited 2024 Jun 13]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK554611

15. Qubty W, Patniyot I. Migraine pathophysiology. Pediatr Neurol 2020;107:1-6.
crossref pmid
16. Mathew AA, Panonnummal R. Cortical spreading depression: culprits and mechanisms. Exp Brain Res 2022;240:733-49.
crossref pmid pdf
17. Wei DY, Goadsby PJ. Cluster headache pathophysiology: insights from current and emerging treatments. Nat Rev Neurol 2021;17:308-24.
crossref pmid pdf
18. Vandenheede M, Schoenen J. Central mechanisms in tension-type headaches. Curr Pain Headache Rep 2002;6:392-400.
crossref pmid pdf
19. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018;38:1-211.

20. Cuvellier JC, Mars A, Vallee L. The prevalence of premonitory symptoms in paediatric migraine: a questionnaire study in 103 children and adolescents. Cephalalgia 2009;29:1197-201.
crossref pmid pdf
21. Mamouri O, Cuvellier JC, Duhamel A, Vallee L, Nguyen The Tich S. Postdrome symptoms in pediatric migraine: a questionnaire retrospective study by phone in 100 patients. Cephalalgia 2018;38:943-8.
crossref pmid pdf
22. Tarantino S, Capuano A, Torriero R, Citti M, Vollono C, Gentile S, et al. Migraine equivalents as part of migraine syndrome in childhood. Pediatr Neurol 2014;51:645-9.
crossref pmid
23. Lagman-Bartolome AM, Lay C. Pediatric migraine variants: a review of epidemiology, diagnosis, treatment, and outcome. Curr Neurol Neurosci Rep 2015;15:34.
crossref pmid pdf
24. Rasquin A, Di Lorenzo C, Forbes D, Guiraldes E, Hyams JS, Staiano A, et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006;130:1527-37.
crossref pmid pmc
25. Batuecas-Caletrio A, Martin-Sanchez V, Cordero-Civantos C, Guardado-Sanchez L, Marcos MR, Fabian AH, et al. Is benign paroxysmal vertigo of childhood a migraine precursor? Eur J Paediatr Neurol 2013;17:397-400.
crossref pmid
26. Humbertclaude V, Krams B, Nogue E, Nagot N, Annequin D, Tourniaire B, et al. Benign paroxysmal torticollis, benign paroxysmal vertigo, and benign tonic upward gaze are not benign disorders. Dev Med Child Neurol 2018;60:1256-63.
crossref pmid pdf
27. Johnson JD, Cocker K, Chang E. Infantile colic: recognition and treatment. Am Fam Physician 2015;92:577-82.
pmid
28. Heinzen EL, Swoboda KJ, Hitomi Y, Gurrieri F, Nicole S, de Vries B, et al. De novo mutations in ATP1A3 cause alternating hemiplegia of childhood. Nat Genet 2012;44:1030-4.
crossref pmid pmc pdf
29. Shapiro HF, Lebel A. Pediatric episodic migraine with aura: a unique entity? Children (Basel) 2021;8:228.
crossref pmid pmc
30. Bear JJ, Gelfand AA, Goadsby PJ, Bass N. Occipital headaches and neuroimaging in children. Neurology 2017;89:469-74.
crossref pmid pmc
31. Lewis DW, Qureshi F. Acute headache in children and adolescents presenting to the emergency department. Headache 2000;40:200-3.
crossref pmid
32. Wijeratne T, Wijeratne C, Korajkic N, Bird S, Sales C, Riederer F. Secondary headaches: red and green flags and their significance for diagnostics. eNeurologicalSci 2023;32:100473.
crossref pmid pmc
33. Dooley J. The evaluation and management of paediatric headaches. Paediatr Child Health 2009;14:24-30.
crossref pmid pmc
34. Lewis DW, Ashwal S, Dahl G, Dorbad D, Hirtz D, Prensky A, et al. Practice parameter: evaluation of children and adolescents with recurrent headaches: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002;59:490-8.
crossref pmid
35. Callaghan BC, Kerber KA, Pace RJ, Skolarus L, Cooper W, Burke JF. Headache neuroimaging: routine testing when guidelines recommend against them. Cephalalgia 2015;35:1144-52.
crossref pmid pmc pdf
36. Teleanu RI, Vladacenco O, Teleanu DM, Epure DA. Treatment of pediatric migraine: a review. Maedica (Bucur) 2016;11:136-43.
pmid pmc
37. Hamalainen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 1997;48:103-7.
crossref pmid
38. Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S, et al. Children’s ibuprofen suspension for the acute treatment of pediatric migraine. Headache 2002;42:780-6.
crossref pmid
39. Suthisisang CC, Poolsup N, Suksomboon N, Lertpipopmetha V, Tepwitukgid B. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010;50:808-18.
crossref pmid
40. Derosier FJ, Lewis D, Hershey AD, Winner PK, Pearlman E, Rothner AD, et al. Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine. Pediatrics 2012;129:e1411-20.
crossref pmid pdf
41. Brousseau DC, Duffy SJ, Anderson AC, Linakis JG. Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac. Ann Emerg Med 2004;43:256-62.
crossref pmid
42. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002;59:1084-8.
crossref pmid
43. Gelfand AA. Pediatric and adolescent headache. Continuum (Minneap Minn) 2018;24(4, Headache):1108-36.
crossref pmid
44. Richer L, Billinghurst L, Linsdell MA, Russell K, Vandermeer B, Crumley ET, et al. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev 2016;4:CD005220.
crossref pmid pmc
45. Patniyot I, Qubty W. Short-term treatment of migraine in children and adolescents. JAMA Pediatr 2020;174:789-90.
crossref pmid
46. Hershey AD. Current approaches to the diagnosis and management of paediatric migraine. Lancet Neurol 2010;9:190-204.
crossref pmid
47. Paruthi S, Brooks LJ, D’Ambrosio C, Hall WA, Kotagal S, Lloyd RM, et al. Recommended amount of sleep for pediatric populations: a consensus statement of the American Academy of Sleep Medicine. J Clin Sleep Med 2016;12:785-6.
crossref pmid pmc
48. Carskadon MA, Tarokh L. Developmental changes in sleep biology and potential effects on adolescent behavior and caffeine use. Nutr Rev 2014;72 Suppl 1:60-4.
crossref pmid pmc
49. Caksen H. Electronic screen exposure and headache in children. Ann Indian Acad Neurol 2021;24:8-10.
crossref pmid pmc
50. Varkey E, Cider A, Carlsson J, Linde M. A study to evaluate the feasibility of an aerobic exercise program in patients with migraine. Headache 2009;49:563-70.
crossref pmid
51. Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia 2011;31:1428-38.
crossref pmid pmc pdf
52. Straube A, Heinen F, Ebinger F, von Kries R. Headache in school children: prevalence and risk factors. Dtsch Arztebl Int 2013;110:811-8.
crossref pmid pmc
53. Orr SL, Potter BK, Ma J, Colman I. Migraine and mental health in a population-based sample of adolescents. Can J Neurol Sci 2017;44:44-50.
crossref pmid
54. Noel ME, Petter M, Parker JA, Chambers CT. Cognitive behavioural therapy for pediatric chronic pain: the problem, research, and practice. J Cogn Psychother 2012;26:143-56.
crossref
55. Ng QX, Venkatanarayanan N, Kumar L. A systematic review and meta-analysis of the efficacy of cognitive behavioral therapy for the management of pediatric migraine. Headache 2017;57:349-62.
crossref pmid pdf
56. Fallah R, Akhavan Karbasi S, Shajari A, Fromandi M. The efficacy and safety of topiramate for prophylaxis of migraine in children. Iran J Child Neurol 2013;7:7-11.
pmid pmc
57. Powers SW, Coffey CS, Chamberlin LA, Ecklund DJ, Klingner EA, Yankey JW, et al. Trial of amitriptyline, topiramate, and placebo for pediatric migraine. N Engl J Med 2017;376:115-24.
crossref pmid pmc
58. Bidabadi E, Mashouf M. A randomized trial of propranolol versus sodium valproate for the prophylaxis of migraine in pediatric patients. Paediatr Drugs 2010;12:269-75.
crossref pmid
59. Hershey AD, Powers SW, Bentti AL, Degrauw TJ. Effectiveness of amitriptyline in the prophylactic management of childhood headaches. Headache 2000;40:539-49.
crossref pmid
60. Eidlitz-Markus T, Dlugatch Y, Haimi-Cohen Y, Goldberg-Stern H, Zeharia A. Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptyline. Pediatr Neurol 2012;46:345-9.
crossref pmid
61. Bakhshandeh Bali M, Rahbarimanesh AA, Sadeghi M, Sedighi M, Karimzadeh P, Ghofrani M. Comparison of propranolol and pregabalin for prophylaxis of childhood migraine: a randomised controlled trial. Acta Med Iran 2015;53:276-80.
pmid
62. Ashrafi MR, Salehi S, Malamiri RA, Heidari M, Hosseini SA, Samiei M, et al. Efficacy and safety of cinnarizine in the prophylaxis of migraine in children: a double-blind placebo-controlled randomized trial. Pediatr Neurol 2014;51:503-8.
crossref pmid
63. Peer Mohamed B, Goadsby PJ, Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: 11 years’ experience, with emphasis on its effect in hemiplegic migraine. Dev Med Child Neurol 2012;54:274-7.
crossref pmid
64. Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, et al. Practice guideline update summary: acute treatment of migraine in children and adolescents: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2019;93:487-99.
crossref pmid
65. Stubberud A, Flaaen NM, McCrory DC, Pedersen SA, Linde M. Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis. Pain 2019;160:762-72.
crossref pmid
66. Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF. A randomized trial to evaluate onabotulinumtoxina for prevention of headaches in adolescents with chronic migraine. Headache 2020;60:564-75.
crossref pmid pmc pdf
67. Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50:921-36.
crossref pmid
68. Marcelo R, Freund B. The efficacy of botulinum toxin in pediatric chronic migraine: a literature review. J Child Neurol 2020;35:844-51.
crossref pmid pdf
69. Ali SS, Bragin I, Rende E, Mejico L, Werner KE. Further evidence that onabotulinum toxin is a viable treatment option for pediatric chronic migraine patients. Cureus 2019;11:e4343.
crossref pmid pmc
70. Cohen SL, Bikson M, Badran BW, George MS. A visual and narrative timeline of US FDA milestones for transcranial magnetic stimulation (TMS) devices. Brain Stimul 2022;15:73-5.
crossref pmid pmc
71. Irwin SL, Qubty W, Allen IE, Patniyot I, Goadsby PJ, Gelfand AA. Transcranial magnetic stimulation for migraine prevention in adolescents: a pilot open-label study. Headache 2018;58:724-31.
crossref pmid pdf
72. Tao H, Wang T, Dong X, Guo Q, Xu H, Wan Q. Effectiveness of transcutaneous electrical nerve stimulation for the treatment of migraine: a meta-analysis of randomized controlled trials. J Headache Pain 2018;19:42.
crossref pmid pmc pdf
73. Tornoe B, Andersen LL, Skotte JH, Jensen R, Jensen C, Madsen BK, et al. Specific strength training compared with interdisciplinary counseling for girls with tension-type headache: a randomized controlled trial. J Pain Res 2016;9:257-70.
crossref pmid pmc
TOOLS
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 1 Crossref
  •   Scopus 
  • 1,811 View
  • 66 Download
Related articles in Ann Child Neurol

Pediatric-Onset CLIPPERS: A Case Report and Literature Review2022 April;30(2)



ABOUT
ARTICLE CATEGORY

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
101, Daehak-ro, Jongno-gu, Seoul 03080, Korea
Tel: +82-2-2072-2364    Fax: +82-2-743-3455    E-mail: editor@annchildneurol.org                

Copyright © 2024 by Korean Child Neurology Society.

Developed in M2PI

Close layer
prev next